6IQ6
Crystal structure of GAPDH
Summary for 6IQ6
| Entry DOI | 10.2210/pdb6iq6/pdb |
| Descriptor | Glyceraldehyde-3-phosphate dehydrogenase, (2Z)-4-methoxy-4-oxobut-2-enoic acid (3 entities in total) |
| Functional Keywords | gapdh, inhibitor, complex, hydrolase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 8 |
| Total formula weight | 289443.84 |
| Authors | Park, J.B.,Park, H.Y. (deposition date: 2018-11-06, release date: 2019-08-28, Last modification date: 2024-11-13) |
| Primary citation | Park, J.B.,Park, H.,Son, J.,Ha, S.J.,Cho, H.S. Structural Study of Monomethyl Fumarate-Bound Human GAPDH. Mol.Cells, 42:597-603, 2019 Cited by PubMed Abstract: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a core enzyme of the aerobic glycolytic pathway with versatile functions and is associated with cancer development. Recently, Kornberg et al . published the detailed correlation between GAPDH and di or monomethyl fumarate (DMF or MMF), which are well-known GAPDH antagonists in the immune system. As an extension, herein, we report the crystal structure of MMF-bound human GAPDH at 2.29 Å. The MMF molecule is covalently linked to the catalytic Cys152 of human GAPDH, and inhibits the catalytic activity of the residue and dramatically reduces the enzymatic activity of GAPDH. Structural comparisons between NADbound GAPDH and MMF-bound GAPDH revealed that the covalently linked MMF can block the binding of the NAD cosubstrate due to steric hindrance of the nicotinamide portion of the NAD molecule, illuminating the specific mechanism by which MMF inhibits GAPDH. Our data provide insights into GAPDH antagonist development for GAPDH-mediated disease treatment. PubMed: 31387164DOI: 10.14348/molcells.2019.0114 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.29 Å) |
Structure validation
Download full validation report
